| 1.57 -0.01 (-0.63%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.06 | 1-year : | 2.41 |
| Resists | First : | 1.76 | Second : | 2.06 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1.46 | Second : | 1.27 |
| MAs | MA(5) : | 1.62  |
MA(20) : | 1.53 |
| MA(100) : | 1.88 |
MA(250) : | 1.87 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.2 |
D(3) : | 74 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 2.95 | Low : | 1.27 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARAY ] has closed below upper band by 45.7%. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.58 - 1.59 | 1.59 - 1.6 |
| Low: | 1.5 - 1.52 | 1.52 - 1.53 |
| Close: | 1.55 - 1.57 | 1.57 - 1.59 |
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Fri, 16 May 2025
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now - MSN
Wed, 07 May 2025
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025 - PR Newswire
Sat, 03 May 2025
Accuray: Tariffs Are The Latest Obstacle For A Company That Has Struggled To Deliver (Rating Downgrade) - Seeking Alpha
Fri, 02 May 2025
Accuray Incorporated (NASDAQ:ARAY) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 01 May 2025
Accuray Inc (ARAY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Global Challenges - Yahoo Finance
Wed, 30 Apr 2025
Accuray Reports Fiscal 2025 Third Quarter Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 103 (M) |
| Shares Float | 100 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 3,950 (K) |
| Shares Short P.Month | 4,530 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0.1 % |
| Operating Margin | 3.7 % |
| Return on Assets (ttm) | 1.7 % |
| Return on Equity (ttm) | 1.4 % |
| Qtrly Rev. Growth | 16.7 % |
| Gross Profit (p.s.) | 1.42 |
| Sales Per Share | 4.51 |
| EBITDA (p.s.) | 0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | 24 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 3.27 |
| Price to Sales | 0.34 |
| Price to Cash Flow | 7.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|